A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas (GBM), the most deadly form of brain tumors.
InvaGen recalls seizure treatment due to leaking sachets
Share this article The product is sold in foil pouches with each sachet containing a 500mg dose of Vigabatrin. Credit: PeopleImages.com – Yuri A /